310430-89-8

Usage

Uses

Used in Pharmaceutical Industry:
1-Amino-3-Methyl-1H-pyrrole-2-carbonitrile is used as a building block for the synthesis of pyrrole-based drugs. Its unique structure allows for the development of new therapeutic agents with potential applications in treating various diseases.
Used in Organic Synthesis:
1-Amino-3-Methyl-1H-pyrrole-2-carbonitrile is used as a key starting material for the production of heterocyclic compounds. Its presence in the synthesis process enables the creation of a wide range of organic compounds with diverse applications.
Used in Medicinal Chemistry:
Due to its structural features and biological activities, 1-Amino-3-Methyl-1H-pyrrole-2-carbonitrile has potential applications in the field of medicinal chemistry. Researchers can leverage its properties to design and develop new drugs with improved efficacy and safety profiles.
It is important to handle and store 1-Amino-3-Methyl-1H-pyrrole-2-carbonitrile with care, as it may pose hazards to human health and the environment if not managed properly.

Upstream product

• 616-43-3 3-methylpyrrole 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 529508-54-1 5-methylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one 
• 310436-79-4 1-amino-2-aminocarbonyl-3-methylpyrrole 

Relevant academic research and scientific papers

PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS

The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R5, R5′, R6, X1, X2, m, and n are described herein.

Pyrrolotriazine inhibitors of kinases

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template

The pyrrolo[2,1-f][1,2,4]triazine nucleus was identified as a novel kinase inhibitor template which effectively mimics the well-known quinazoline kinase inhibitor scaffold. Attachment of a 4-((3-chloro-4-fluorophenyl)amino) substituent to the template provided potent biochemical inhibitors of the tyrosine kinase activity of EGFR, as well as inhibition of cellular proliferation of the human colon tumor cell line DiFi. Attachment of a 4-((3-hydroxy-4-methylphenyl)amino) substituent provided potent inhibitors of VEGFR-2 which also showed effects on the VEGF-dependent proliferation of human umbilical vein endothelial cells. Biological activity was maintained with substitution at positions 5 or 6, but not 7, suggesting that the former positions are promising sites for introducing side chains which modulate physicochemical. properties. Preliminary inhibition studies with varying ATP concentrations suggest that, like the quinazoline-based kinase inhibitors, the pyrrolotriazine-based inhibitors bind in the ATP pocket.